Metadata supporting the article: Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
Creators: name: Almekinders, Mathilde M.
name: Schaapveld, Michael
name: Thijssen, Bram
name: Visser, Lindy L.
name: Bismeijer, Tycho
name: Sanders, Joyce
name: Isnaldi, Edoardo
name: Hofland, Ingrid
name: Mertz, Marjolijn
name: Wessels, Lodewyk F.A.
name: Broeks, Annegien
name: Hooijberg, Erik
name: Zwart, Wilbert
name: Lips, Esther H.
name: Desmedt, Christine
name: Jelle Wesseling On Behalf Of The PRECISION (PREvent Ductal Carcinoma In Situ Invasive Overtreatment Now)
Publisher: name: figshare
Year: 2021
Subjects: subject: Biological Techniques
subject: Cancer
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Medicine
subject: Biomarkers
subject: 111201 Cancer Cell Biology
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: 111202 Cancer Diagnosis

description: Although Ductal Carcinoma <i>In Situ </i>(DCIS) is a non-obligate precursor to ipsilateral invasive breast cancer (iIBC), most DCIS lesions remain indolent. Hence, overdiagnosis and overtreatment of DCIS is a major concern. There is an urgent need for prognostic markers that can distinguish harmless from potentially hazardous DCIS. In this study, the authors hypothesized that breast adipocyte hypertrophy in DCIS is associated with risk of subsequent iIBC.<br> <b>Data access</b>: Histopathology and immunohistochemistry data, and data on adipocyte measurements using digital pathology, that support the findings of this study, are not publicly available in order to protect patient privacy. The data will be made available upon reasonable request from the corresponding author, Prof. Jelle Wesseling, email address: j.wesseling@nki.nl.<br> <b>Study approval and patient consent: </b>The study was approved by the review boards of the Netherlands Cancer Registry and the Dutch National Pathology Automated Archive (PALGA). The secondary use of tissue and data in this study are covered by an opt-out regimen conform Dutch regulations, the Code of Conduct of Federa-COREON and the international Guideline on Good Clinical Practice. The study also meets the General Data Protection Regulation (GDPR) criteria that came into effect on 25 May 2019. <br> <b>Study aims and methodology</b>: Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive breast cancer. DCIS incidence has increased manifold since the implementation of population-based mammographic breast cancer screening. DCIS is generally treated with surgery, often followed by radiotherapy and sometimes adjuvant hormonal therapy. The majority of patients with primary DCIS, however, will not develop a subsequent ipsilateral invasive breast cancer (iIBC), suggesting overdiagnosis and overtreatment. Clinicians urgently need prognostic biomarkers to distinguish hazardous from indolent DCIS for adequate risk stratification. In this study, the authors investigated mammary adiposity in relation to risk of subsequent iIBC after primary DCIS. This retrospective study involved 276 patients. Women with primary DCIS that developed iIBC were defined as cases. Controls correspond to women with primary DCIS that did not develop iIBC for at least the same follow-up duration as time to iIBC in the corresponding case. Cases and controls were matched for age at DCIS diagnosis (plus-minus 0-6 months). Cases and controls were not matched for year of diagnosis. Intact adipose tissue was assessed in H&amp;E slides from 108 cases and 168 controls. The following are described in more detail in the related article and its supplementary methods: adipocyte measurements with digital pathology, histopathology, immunohistochemistry, and statistical analysis.<br> <b>Data supporting the figures, tables and supplementary tables:</b> Data supporting figure 2, tables 1-3, and supplementary table 3: Dataset <b>20201023_npj_breast_cancer.csv</b>, in .csv file format. Data supporting figure 4: Datasets <b>20201023_npj_breast_cancer.csv</b> and <b>20200707 cox2_adipo_area.csv</b>, both in .csv file format. Data supporting supplementary table 2: Dataset <b>20201113_CLS.csv</b>, in .csv file format.